Drug Information

Drug General Information
Drug ID
D0A4IJ
Former ID
DAP000704
Drug Name
Abacavir
Synonyms
Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Approved [550653]
Therapeutic Class
Anti-HIV Agents
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C14H18N6O
Canonical SMILES
C1CC1NC2=NC(=NC3=C2N=CN3C4CC(C=C4)CO)N
InChI
1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
InChIKey
MCGSCOLBFJQGHM-SCZZXKLOSA-N
CAS Number
CAS 136470-78-5
PubChem Compound ID
441300
PubChem Substance ID
9826, 603460, 612310, 7978623, 10298786, 14775540, 14799909, 26757979, 26757980, 36885172, 46505718, 51091399, 57403623, 70504220, 76364492, 81092778, 85612588, 92729708, 103463308, 104052305, 104625144, 126654052, 128575040, 131298145, 135025044, 136345668, 137006087, 142178555, 160845918, 160964383, 162011475, 162176802, 163621096, 163686421, 163883088, 164814948, 165235811, 175267614, 175442679, 179149865, 184545024, 186014779, 196109919, 223516662, 223703089, 223704757, 223900945, 226424139, 241033176, 241383802
ChEBI ID
ChEBI:2360
SuperDrug ATC ID
J05AF06
SuperDrug CAS ID
cas=136470785
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Inhibitor [537321]
References
Ref 550653Abacavir (marketed as Ziagen) and Abacavir-containing Medications. FDA. 2008.
Ref 537321Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Curr HIV Res. 2009 May;7(3):320-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.